Objective: The aim of this study was to assess the genetic effects of the vascular endothelial growth factor (VEGF) pathway on retinopathy of prematurity (ROP).
Introduction
Retinopathy of prematurity (ROP) is one of the critical complications in preterm infants because of the most common cause of blindness in childhood. The formation of retinal and vitreous membranes leads to retinal detachments in severely affected infants. Abnormal and progressive neovascularization is the most important pathophysiological mechanism in this setting. Recent experimental studies indicated that growth factors including growth hormone, insulin-like growth factor-1 and vascular endothelial growth factor (VEGF) are involved in the pathogenesis of ROP. 1 VEGF, a specific mitogen for vascular endothelial cells, is essential for neovascularization in the tissue. VEGF gene polymorphisms have been reportedly associated with proliferative diabetic retinopathy 2 and age-related degeneration. 3 These retinal diseases might share the disease process of vasculopathy with ROP. Several lines of studies reported that the gene polymorphisms of VEGF and its associated molecules would be involved in development of ROP. 4, 5 On the other hand, a lack of or negligible association has been indicated between the genetic background and the evolution of ROP. 6, 7 To the best of our knowledge, the clinical impact of gene polymorphisms on the development of ROP has not yet been confirmed.
Besides the genetic predisposition, a variety of causative factors have been proposed for the development of ROP. Low birth weight, low gestational age and prolonged oxygen therapy have been consistently believed to raise the substantial risk of ROP. 8 Other putative factors have been reported in the association with ROP, including mechanical ventilation, 8 low Apgar score, 8 steroid therapy, 9 small-for-gestational age, 10 male gender, 11 blood transfusion 12 and multiple birth.
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However, it remains unknown how and which factors contribute to the initiation and/or progression of ROP under the mutual interaction. Insulin-like growth factor-1 and VEGF cooperatively control the physiological development of ocular blood vessels of the fetus and the infants. To minimize the late effects on the preterm survivors, the prophylactic and therapeutic modality for ROP should be optimized according to the individual infants.
In this study, we analyzed VEGF and VEGF-receptor gene polymorphisms in preterm infants who developed or did not develop ROP. To establish the best practice for the control of ROP, the relationship between the gene polymorphisms and clinical factors for the evolution and severity of ROP was assessed in a Japanese population.
Methods

Patients
Of the 614 infants admitted to the tertiary center of a neonatal intensive care unit at Kyushu University Hospital between 2004 and 2007, 247 infants were born within less than 35 weeks of gestational age. Of the preterm infants, 204 were prospectively enrolled in this study. Exclusion criteria were chromosomal aberrations, major anomalies and inherited diseases. Informed consent, approved by Kyushu University Hospital Ethical Committee, was obtained from their guardians. Table 1 shows the clinical characteristics of patients studied. Patients who suffered from ROP had lower Apgar scores at 1 and 5 min, lower gestational ages and lower birth weights than those who did not. The frequencies of respiratory distress syndrome, oxygen dependency at 36 weeks of post-conceptual age, bronchopulmonary dysplasia and infections were higher in ROP infants than in non-ROP infants. As for the treatment, ROP patients frequently received more blood transfusions, dexamethasone therapy, management for patent ductus arteriosus and surgery for intestinal perforation, and also required longer oxygen therapy and intermittent mechanical ventilation than non-ROP patients. There were no differences in the sex, single or multiple birth and mode of delivery, small-forgestational age and periventricular leukomalacia between ROP and non-ROP patients. All infants underwent ophthalmological examinations to assess neovascular proliferation and stage according to the international classification for ROP. 13 Analyses of gene polymorphisms Peripheral blood samples were collected at the time of routine examinations during hospitalization. Genomic DNA was conventionally extracted from peripheral blood mononuclear cells with the QIAamp DNA Blood Kit (QIAGEN, Tokyo, Japan). Restriction fragment length polymorphism analysis of VEGF g.À634 G>C and g. þ 13553 C>T single-nucleotide polymorphisms was carried out according to the established methods.
14 The KDR g.À4422(AC) 11 to 14 dinucleotide repeat polymorphism in all subjects was determined as described in our previous report. 15 The Flt-1 c.À6724(TG) 13 to 23 site was amplified by polymerase chain reaction, and the genotyping of gene microsatellite polymorphisms was determined by a fluorescence-based technique as described previously. 16 Relative severity of ROP according to gestational age ROP stages were most closely linked with gestational age. Median ROP stages in each gestational age were as follows: 3 in infants who were born at 22 to 25 weeks of gestational age, 2 in infants at 26 weeks of gestational age, 1 in infants at 27 to 29 weeks of gestational age and 0 in infants at 30 to 34 weeks of gestational age. The relative severity was defined according to the gestational age. Based on the equation score ¼ ROP stageÀthe median stage of each gestational age group, X1 was classified as 'severe', 0 as 'moderate' and pÀ1 as 'non-severe ROP'.
Statistics
Continuous data were compared by Wilcoxon-signed rank-sum test and categorical data were compared using Fisher's exact test among the groups. Distribution of allele and genotype frequencies between the groups was compared using Pearson's w 2 -test or logistic regression analysis. Multiple logistic regression analysis was conducted to mutually adjust for explanatory variables. Non-severe ROP for gestational age, advanced ROP (X stage 3) and the development of ROP (X stage 1) were used as the dependent variables. The explanatory variables were each gene polymorphism, birth weight, gestational age, multiple birth, Apgar score (5-min), mode of delivery, duration of intermittent mechanical Table 2 ). The genotype distribution of VEGF g. þ 13553 C>T polymorphisms differed among the groups of severity (Table 2b , P ¼ 0.030). The frequency of TT genotype was higher in non-severe ROP infants than observed in others (moderate and severe ROP infants) (P ¼ 0.006), but was not different between severe ROP infants and others (non-severe and severe ROP infants). The frequencies of VEGF g.À634 G>C, KDR g. þ 4422(AC) 11 to 14, and Flt-1 c.À6724 (TG) polymorphisms did not differ among the groups of relative severity (Table 2a , c and d).
The effect of gene polymorphism on the relative severity of ROP was assessed by logistic regression analysis ( Table 3 ). The TT genotype of VEGF g. þ 13553 C>T showed a higher odds ratio for non-severe ROP than the CC genotype (P ¼ 0.006). The presence of C allele had a significantly lower odds ratio for non-severe ROP subjects (P ¼ 0.006). No other gene polymorphisms were associated with the relative severity of ROP.
Clinical risk factors for the development and severity of ROP To address the optimal treatment for ROP, multivariate analyses were performed to determine the clinical variables, including gene polymorphisms influencing the risk of ROP (X stage 1) or advanced ROP (X stage 3). The multiple regression analysis revealed that low gestational age (P<0.001), single birth (P ¼ 0.012), small-for-gestational age (P ¼ 0.019), longer oxygen therapy (P ¼ 0.025) and male gender (P ¼ 0.040) were the independent risk factors for the development of ROP, and that low birth weight (P ¼ 0.002), times of blood transfusion (P ¼ 0.001) and respiratory distress syndrome (P ¼ 0.004) were those for advanced ROP among ROP patients (Table 4) . When the C allele VEGF polymorphism in ROP T Kusuda et al of VEGF g. þ 13553 was added to the model, it was not selected as a significant risk factor for advanced ROP (P ¼ 0.13). No polymorphism was selected as the risk factor for the development and severity of ROP.
Discussion
This study revealed a significant association between the TT genotype of VEGF g. þ 13553 C>T and non-severe ROP for gestational age. Low birth weight, number of times of blood transfusion, respiratory distress syndrome and oxygen dependency at 36 weeks were indicated as the risk factors for advanced ROP (X stage 3). On the other hand, no polymorphisms were selected as variables influencing the significant risk for the development and severity of ROP by multivariate analyses. The VEGF g. þ 13553 C>T polymorphism might be involved in the progression of ROP, although it could have less clinical impact on the evolution of ROP than other factors. Chen and Smith 1 explained that ROP occurs in two phases of the disease process. In the first phase, premature birth leads to a cessation of physiological vascular growth of the retina that would normally occur in utero, as well as an inhibition of the ordinary neural development of the retina. In the second phase of ROP, hypoxia induces retinal neovascularization, which is promoted by insulin-like growth factor-1 and VEGF signaling through the activation of p44/42 mitogen-activated protein kinase in a coordinated manner. Renner et al.
14 reported that plasma VEGF levels were lower in carriers of the VEGF g. þ 13553 T allele than in non-carriers, and suggested that an alternative VEGF protein associated with VEGF g. þ 13553 C>T polymorphism might be involved in susceptibility to ROP. In this study, the TT genotype of VEGF g. þ 13553 was associated with non-severe ROP. It may raise the possibility that low production of VEGF protein in the TT genotype carriers hampers the progression in the second phase of ROP, although serum VEGF concentrations were not measured in this study. As for the VEGF g.À634 G>C polymorphism, Vannay et al. 5 reported that heterozygous and homozygous carriers of the C allele had a higher likelihood of developing ROP requiring treatment even after adjustment for other risk factors of ROP, including gestational age, oxygen therapy and sex. On the other hand, Kwinta et al. 17 showed no difference in the frequency of VEGF g.À634 G>C polymorphism between low birth weight infants with and without ROP, and serum VEGF levels in the patients did not depend on the VEGF polymorphism. The frequency of VEGF g.À634 G>C polymorphism did not differ among Japanese preterm infants having various ROP stages. Recently, Dunai et al. 6 have shown a negligible contribution of genetic variants to the risk and severity of ROP by a metaanalysis on the published data for VEGF (including g.À634 G>C, but not g. þ 13553 C>T polymorphism), insulin-like growth factor-1 receptor (G þ 3174A), angiopoietin II, estrogen receptor PvuII Pp and endothelial NO-synthase. These controversial results of genetic polymorphisms might be explained in part by the sample size and/or distinct races of study population. Genotypes of VEGF pathway may explain the unusual progression of advanced ROP. 18 There may be less clinical effect of genetic predisposition on the development of ROP than other treatment factors.
Flt-1 and KDR genes encode VEGF receptor-1 and receptor-2, respectively. The major function of the VEGF pathway depends on the signaling through VEGF receptor-2. Pieh et al. 19 reported elevated plasma levels of soluble VEGFR-2 and soluble Tie2 in active ROP patients. Kwinta et al. 17 concluded that serum concentrations of VEGF and soluble VEGFR-1 on the 10th day of life did not differ significantly among patients with no ROP, ROP not requiring treatment and ROP requiring laser or cryotherapy. We found no significant association between KDR g.À4422 (AC) 11 to 14 or Flt-1 c.À6724 (TG) 13 to 23 dinucleotide repeat polymorphism, and development of severe ROP. Genetic variations of VEGF receptor might have negligible effects on the development of ROP in Japanese preterm infants.
Supplemental oxygen therapy for premature infants is one of the most important factors in developing ROP. As for the treatment-related risk factor, duration of oxygen therapy was indicated for the onset of ROP, while oxygen dependency at 36 weeks, blood transfusions and respiratory distress syndrome were selected for the development of X stage 3 ROP (Table 4) . Premature infants having prolonged ventilator support are at high risk of developing severe ROP requiring treatment. 12 High oxygen concentration of blood directly influenced the retinal angiogenesis in an animal model of ROP and this state is known as oxygen-induced retinopathy. 20 On the other hand, optimal supplementation of oxygen might have an inhibitory effect on the progression of ROP because of suppressing the overexpression of VEGF in the second stage of ROP. 1 These findings may raise the need of optimal oxygen therapy that could overcome the individual VEGF responses and reduce the risk of both ocular and pulmonary complications in premature infants. In conclusion, the genetic polymorphisms in VEGF and its receptor system are less or not sensitive predictors of ROP compared with other clinical parameters.
